It is found that, while AF3 can perform well in favourable settings, this performance is uneven across applications and its predictions and use of confidence metrics will depend strongly on the specific application area and must be interpreted with respect to training-set overlap.
Abstract
Structure prediction models have moved from single proteins to assemblies that include diverse biomolecules and their modifications. AlphaFold3 (AF3) and related models extended structural modelling via an all-atom framework, opening many new potential applications in structural biology. We evaluate how well the new capabilities of AF3 translate into application tasks in diverse areas: prediction of ubiquitinated protein structures, T-cell receptor (TCR)-epitope recognition, antibody-antigen complexes, protein-RNA and protein-lipid interactions. We find that, while AF3 can perform well in favourable settings, this performance is uneven across applications. In RNA-target predictions, the model confidence fails to separate genuine from decoy interaction partners and in several tasks accuracy depends on the presence of related complexes in the training set. Taken together, our assessment is more cautious than for AF2, whose gains in modelling monomers and complexes were clear and broadly generalisable. AF3’s extension to new biomolecule types shows less consistent performance and generalisation. AF3 can be a powerful tool for hypothesis generation and prioritisation, but its predictions and use of confidence metrics will depend strongly on the specific application area and must be interpreted with respect to training-set overlap. We expect that the benchmarks provided here will serve for testing of future developments in the structure prediction field.
Protein structure predictors achieve high single-state accuracy, but it remains unclear whether they can recover functionally relevant conformational ensembles or account for the presence of ligands and/or binding partners. Here, we benchmark AlphaFold3, Boltz-2, Chai-1, and BioEmu on four canonical multi-state proteins (Pf-MATE, LAO, SecA, and β2AR), quantifying state bias and sampling breadth against experimental reference structures. Models frequently default to a dominant state represented in the PDB; small-molecule ligands have weak or inconsistent effects, while large protein partners drive clear conformational switching between states. Multiple sequence alignment (MSA)-based approaches (AF-Cluster and random subsampling) recapitulate similar biases, indicating that this behavior is not unique to newer architectures. These results underscore current limitations for multi-state protein structure prediction and structure-guided ligand discovery. TOC Graphic
Muhui Ye, Yu-Hong Wang, M. Brogi et al.· bioRxiv· 0 citations
Accurate prediction of peptide structures and peptide-receptor complexes is essential for rational peptide drug development. However, the inherent conformational flexibility of short and disordered peptides presents a fundamental challenge. The AlphaFold model series, which has progressed from AlphaFold2 through AlphaFold-Multimer to AlphaFold3, has substantially advanced computational peptide structure prediction through innovations in geometric reasoning (invariant point attention) and interface-focused confidence metrics (ipTM score), achieving high accuracy for both monomeric peptide structures and multi-chain complexes. However, these models output static conformations, whereas many bioactive peptides adopt their functional conformations only upon binding-often corresponding to low-probability states that static predictions may overlook, leading to failures in virtual screening. This review synthesizes recent advances in the AlphaFold series for peptide studies and applications, discusses their current strengths in structure prediction and receptor-binding analysis, and examines the limitations in capturing conformational dynamics, transient interactions, and chemical modifications. Recent studies have suggested that integrated computational strategies that combine AlphaFold predictions with molecular dynamics simulations, free energy calculations, and ensemble sampling to enhance predictive accuracy and better represent the dynamic nature of peptide-drug interactions. These complementary approaches position AlphaFold as a central computational platform in structure-guided peptide drug design, enabling more efficient lead identification and optimization while bridging the gap between static computational predictions and the complex biophysical reality of peptide therapeutics.
Artificial Intelligence has had a profound impact on the biological sciences, and in particular has accelerated research on protein form and function. Enzymes are no exception: a surge of predictive models have been recently developed to address a range of enzyme tasks. Models addressing enzyme-substrate (ES) or enzyme-reaction (ER) compatibility could be especially valuable for enzyme annotation, biosynthetic pathway elucidation, and biocatalyst retrieval, the central challenge of which is the identification of a true catalyst (or truly compatible reaction) among many similar candidates. While existing models report strong performance on alternative benchmarks, less is known about their capabilities in this regime. Herein, we benchmark four recently released ES and ER prediction models, using tasks and datasets tailored to this setting. We first show that two representative ES prediction models perform near random baselines across two enzyme families when considering enzymes and substrates not encountered during training. To evaluate additional models across a consistent dataset, we next assemble the largest cytochrome P450 (CYP) reaction dataset to date, 2,922 reactions across 768 enzymes, and construct a CYP ranking benchmark requiring the correct enzyme to be prioritized among all CYPs in its native organism. We again find that most models do not outperform sequence-based (BLAST) baselines even after fine-tuning. We finally adapt the bimolecular structure prediction model Boltz to ES prediction by training supervised classifiers on residue-ligand pair embeddings, and show that this approach consistently surpasses the BLAST baselines on our CYP ranking benchmark. Together, our results argue for more discovery-relevant benchmarking and suggest that interaction-aware representations from full biomolecular complexes may provide a promising basis for enzyme prioritization.
Elizabeth H. Mahood, N. Komorníková, Tom'avs Pluskal et al.· 0 citations
Predicting the location of metal-binding sites in proteins is crucial for fundamental biological questions and biotechnological applications. Over the past decade, the rise in metal-bound protein structures in the Protein Data Bank, combined with advanced statistical models such as deep learning, has accelerated the development of metal-binding site prediction tools. Several approaches are now available, offering high-quality benchmarks and predictive performance. Our initial development in this area is BioMetAll, whose first version was based on backbone pre-organization. Here, we introduce its second version, featuring two major updates: 1) metal-specific scoring functions and 2) prediction using backbone geometry alone or in combination with first coordination sphere descriptors. Apart from demonstrating metal sensitivity and yielding better benchmarking results, this new version allows the assessment of the influence of considering the metal’s first coordination sphere versus backbone pre-organization on how metallic species bind to proteins.
These findings provide practical guidance for integrating open-source protein structure prediction models into AI-driven nanobody discovery pipelines while highlighting the need for improved generalization across antigens.
Yannick Vogt, Rebekka Roßberg, Jan Habermann et al.· Frontiers in Bioinformatics· 0 citations